Skip to main content

Table 1 Baseline clinicopathologic and prognostic characteristics of 184 patients with metastatic renal cell carcinoma (mRCC)

From: Comparison of efficacy, safety, and quality of life between sorafenib and sunitinib as first-line therapy for Chinese patients with metastatic renal cell carcinoma

Variable

Total [cases (%)]

Sorafenib group [cases (%)]

Sunitinib group [cases (%)]

P value

Total

184

110

74

 

Sex

   

0.336

 Man

141 (76.6)

87 (84.3)

54 (73.0)

 

 Woman

43 (23.4)

23 (25.7)

20 (27.0)

 

Age (years)

   

0.152

 <65

139 (75.5)

79 (71.8)

60 (81.1)

 

 ≥65

45 (24.5)

31 (28.2)

14 (18.9)

 

Histology

   

0.872

 Clear cell

176 (95.7)

105 (95.5)

71 (96.0)

 

 Others

8 (4.3)

5 (4.5)

3 (4.0)

 

Prior nephrectomy

   

0.516

 Yes

150 (81.5)

88 (80.0)

62 (83.8)

 

 No

34 (18.5)

22 (20.0)

12 (16.2)

 

Prior cytokine therapy

   

0.118

 Yes

60 (32.6)

31 (28.2)

29 (39.2)

 

 No

124 (67.4)

79 (71.8)

45 (60.8)

 

Fuhrman grade

   

0.636

 1–2

106 (57.6)

64 (58.2)

42 (56.8)

 

 3–4

64 (34.8)

35 (31.8)

29 (39.2)

 

 Unknown

14 (7.6)

11 (10.0)

3 (4.0)

 

Number of metastatic sites

   

0.084

 1

134 (72.8)

75 (68.2)

59 (79.7)

 

 ≥2

50 (27.2)

35 (31.8)

15 (20.3)

 

Metastatic sites

 Lung

139 (75.5)

81 (73.6)

58 (78.4)

0.463

 Lymph nodes

44 (23.9)

29 (26.4)

15 (20.3)

0.342

 Bone

19 (10.3)

12 (10.9)

7 (9.5)

0.751

 Liver

15 (8.2)

12 (10.9)

3 (4.1)

0.096

 Others

13 (7.1)

7 (6.4)

6 (8.1)

0.651

MSKCC grade

   

0.598

 Favorable

86 (46.7)

49 (44.6)

37 (50.0)

 

 Intermediate

73 (39.7)

46 (41.8)

27 (36.5)

 

 Poor

25 (13.6)

15 (13.6)

10 (13.5)

 

IMDC risk

   

0.199

 Good

100 (54.3)

57 (51.8)

43 (58.1)

 

 Intermediate

73 (39.7)

44 (40.0)

29 (39.2)

 

 Poor

11 (6.0)

9 (8.2)

2 (2.7)

 
  1. MSKCC Memorial Sloan-Kettering Cancer Center, IMDC International Metastatic Renal Cell Carcinoma Database Consortium